Navigation Links
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
Date:3/19/2013

Division Chair, University of Wisconsin, "The data presented at AAN from the development program for USL261 support the safety profile and favorable pharmacokinetics/pharmacodynamics of USL261 in healthy volunteers.  These findings support the further development of USL261 for seizure rescue in patients with intermittent bouts of increased seizure activity, a population for which few treatment options are currently available."

USL261 (Intranasal Midazolam) Data  

USL261 data presented at AAN 2013 examined the pharmacokinetics, pharmacodynamics, safety, and tolerability of USL261 in healthy volunteers.  In this study, increasing USL261 doses corresponded with an apparent linear increase in midazolam exposure, with all doses demonstrating rapid time to maximal plasma concentration (10 – 15 min).  Researchers concluded that USL261 dosed up to 7.5 mg was generally well tolerated and did not result in excessive or prolonged sedation or psychomotor impairment.  Further, when compared with an equivalent dose of injectable midazolam delivered intranasally, USL261 demonstrated improved midazolam bioavailability with similar pharmacodynamic effects and safety/tolerability profiles.  

Abstracts of the poster presentations can be found online at: http://www.aan.com 

  • Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration
    P02.211. Session P02:  Epilepsy:  Novel Therapeutics and Basic Science
  • Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam
    P02.212. Session P02:  Epilepsy:  Novel Therapeutics and Basic Science

About Epilepsy

Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
2. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
3. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
4. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
5. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
6. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
7. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
8. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
9. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
10. HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
11. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Arbor, Mich. Every day, their baby stopped breathing, ... to his lungs. April and Bryan Gionfriddo watched helplessly, ... , "Quite a few doctors said he had a ... April Gionfriddo, about her now 20-month-old son, Kaiba. "At ... we would take it and run with it." , ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Graphite ... self-lubricating bushings mounted in stainless steel pillow ... properties of GRAPHALLOY with the application and installation ... Steel Pillow Blocks work exceptionally well when ... or hostile liquids such as acids, alkalies, hydrocarbons, ...
(Date:5/23/2013)... 2013 PuraMed BioScience ® , Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced that ... company based on low market capitalization valuation. ... Natural Product to Treat Migraine Headaches , ... Competitor , Currently Available Nationwide at Walgreen,s ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... , , ... that it has entered into a cooperative research and development ... (NIAID), part of the National Institutes of Health (NIH), to ... mycobacteria (NTM) lung infections. , , Transave ...
... BEIJING, July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, ... a growing developer and,producer of prescriptions drugs and ... Republic of China, today reported it received notice,of ... of the People,s,Republic of China for its innovative ...
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call on ... quarter 2009 financial results. Access to the discussion may be obtained as follows: ... 11:30 AM ET /8:30 AM PT, Date: ... or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor relations ...
Cached Biology Technology:Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 2Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 3Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria 4Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 3Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
(Date:5/23/2013)... overall health, development, and academic success of children, ... that all students have opportunities to engage in ... or moderate-intensity physical activity, says a new report ... suggest that only about half of school-age children ... and development. The report recommends that most ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... eyes are closed, the visual centers in our brain are ... in the last few years that the magnitude of sense-related ... is quite similar to that of one exposed to a ... of that activity, explaining why, even though our sense centers ...
... ESA is now gearing up to return to Russia to ... now envisaged for launch on 16 March 2009. This follows ... Rockot launcher that delayed the launch of GOCE by Eurockot ... has just arrived at the Plesetsk Cosmodrome in northern Russia ...
... at Albert Einstein College of Medicine of Yeshiva University have ... and causes disease. The study, published in ... ( PNAS ), may help scientists develop new therapies ... These fungal infections occur most commonly in those with compromised ...
Cached Biology News:Behind closed eyes 2March launch planned for ESA's gravity mission 2Scientists discover how deadly fungus protects itself 2
... A very potent Rnase free ... over a broad range of ... protein does not inhibit SP6, ... AMV and M-MLV reverse transcriptase ...
... kit, 110 to 220 V, enables ... doubles flow rates and valve capacity ... kit includes the Maximizer base unit, ... tubing kit, system cable 30, and ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: